Phase Ib proof-of-concept trial investigating the pharmacokinetics, pharmacodynamics and tolerability of CP 024, an intranasal formulation of somatropin, versus subcutaneously administered Omnitrope in healthy volunteers

Trial Profile

Phase Ib proof-of-concept trial investigating the pharmacokinetics, pharmacodynamics and tolerability of CP 024, an intranasal formulation of somatropin, versus subcutaneously administered Omnitrope in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2013

At a glance

  • Drugs Somatropin (Primary) ; Somatropin (Primary)
  • Indications Somatotropin deficiency
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 21 Nov 2013 New trial record
    • 12 Feb 2013 Status changed to completed, based on information in a Critical Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top